Figure 6
From: The impact of KRAS mutations on VEGF-A production and tumour vascular network
VEGF-A expresion in KRAS ASP13 and CYS12 tumours. A) VEGF-A mRNA and Angiopoietin-2 levels detected by real time PCR in tumour tissue. VEGF-A was overexpressed in ASP13 tumours when compared with CYS12 (ASP13: 0.9 ± 0.2 2-ΔCT vs CYS12: 0.4 ± 0.1 2-ΔCT; P = 0.04) while mRNA Angiopoietin-2 levels were not different. B) VEGF-A protein levels measured by ELISA were shown as pg of VEGF per mg of tumour lysate. VEGF-A were higher in ASP13 tumours (ASP13: 5.5 ± 0.98 μg VEGF-A/mg tumour lysate vs CYS12: 2.5 ± 0.6 μg VEGF-A/mg tumour lysate; P = 0.02). C) Illustrative VEGF-A immunostaining is shown for each mutant.